

Study Record: PHS Human Subjects and Clinical Trials Information

Section 1 - Basic Information

Required, must be unique (600 characters max). If a CT, title must match the "Official Title" registered in ClinicalTrials.gov. If Title is not the same as the one on the IRB and/or the PI name on the IRB does not match the lead of the study, then an IRB letter of congruence is needed.

1.1. * Study Title (each study title must be unique)* Is this Study Exempt from Federal Regulations?

1.2. Exemption Number Multiple selections are permitted Yes No

1 2 3 4 5 6 7 8

1.3. * Clinical Trial Questionnaire: For application due dates on or after May 25, 2026, determine whether your project qualifies as a clinical trial, a basic experimental study involving humans (BESH), or an observational study involving humans (see below).

1.4.a. Does the study involve human participants?	1.4.b. Are the participants prospectively assigned to an intervention?	1.4.c. Is the study designed to evaluate the effect of the intervention on the participants?	1.4.d. Is the effect that being evaluated a health-related biomedical or behavioral outcome?	Study Type
Yes	Yes	Yes	Yes	Clinical Trial
Yes	Yes	Yes	No	BESH
Yes	No	No	Yes	Observational
Yes	No	No	No	Observational

1.4. Provide the ClinicalTrials.gov Identifier (e.g., NCT87654321) for this trial, if applicable

Registration of a CT is required 21 days after enrollment of the first participant; then include the NCT# on the next RPPR.

Section 2 - Study Population Characteristics

2.1 Conditions or Focus of Study Can enter up to 20 conditions. Identify the name(s) of the disease(s) or condition(s) you are studying, or the focus of the study. Use appropriate descriptors from NLM's Medical Subject Headings (MeSH) so the application can be categorized. Include an entry for each condition. If a CT, this field should match the ClinicalTrials.gov field Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study.

x

2.2. Eligibility Criteria List the study's inclusion and exclusion criteria; if a CT, should match the ClinicalTrials.gov field (Eligibility Criteria).

NOTE for 2.3 – 2.4: If using an existing dataset, resource, or samples that may have been collected as part of a different study, you must address inclusion as above and provide details about the sex/gender, race, and ethnicity for the existing dataset/resource and justify the details as appropriate to the scientific goals of the proposed study.

2.3. Age Limits Minimum Age Maximum Age

For CT, matches ClinicalTrials.gov field (Age Limits).

2.3.a. Inclusion of Individuals Across the Lifespan

Exclusion of any specific age or age range group (e.g., children or older adults) should be justified in this section.

2.4. Inclusion of Women and Minorities

Describe the planned distribution of subjects by sex/gender, race, and ethnicity and scientifically justify any exclusions.

2.5. Recruitment and Retention Plan

Required unless research is X4 and X4 is the only exemption chosen, or if an existing database is being used.

2.6. Recruitment Status choose from menu

Not required for X4. For CTs, should match ClinicalTrials.gov field (Overall Recruitment Status).

2.7. Study Timeline

Optional except for CT

2.8 Enrollment of First Participant Required unless it's an existing database or only X4 research

2.9 Inclusion Enrollment Report(s) Required unless it's only X4 research. A Study Record can have more than one IER and IERs should represent each participant once and not duplicate participants in different IERs. If it is a CT, use one Study Record with one IER, so that it will match up with what will be registered with clinicaltrials.gov. Manually enter planned enrollment. For RPPRs, when entering Cumulative enrollment, use the Participant Level Data template, which will auto-populate ages. For RPPRs for CTs, first update enrollment at clinicaltrials.gov and then upload the data into the HSS system.

Inclusion Enrollment Report

Remove Inclusion Enrollment Report

1. Inclusion Enrollment Report Title (unique title if more than 1 IER)

2. Using an Existing Dataset or Resource? Yes No

If YES, enter enrollment in the Cumulative Table and not under Planned Enrollment.

3. Enrollment Location Type Domestic Foreign

IDeA: foreign sites not allowed; non-IDeA Domestic sites allowed only if funded by non-IDeA sources

4. Enrollment Country(ies) optional

Add New Country

5. Enrollment Location(s) optional. This is the site of the research not the recruitment site

6. Comments (optional)

Planned

Racial Categories	Ethnic Categories				Total
	Not Hispanic or Latino		Hispanic or Latino		
	Female	Male	Female	Male	
American Indian/Alaska Native	<input type="text" value="0"/>	<input type="text" value="0"/>	<input type="text" value="0"/>	<input type="text" value="0"/>	0
Asian	<input type="text" value="0"/>	<input type="text" value="0"/>	<input type="text" value="0"/>	<input type="text" value="0"/>	0
Native Hawaiian or Other Pacific Islander	<input type="text" value="0"/>	<input type="text" value="0"/>	<input type="text" value="0"/>	<input type="text" value="0"/>	0
Black or African American	<input type="text" value="0"/>	<input type="text" value="0"/>	<input type="text" value="0"/>	<input type="text" value="0"/>	0
White	<input type="text" value="0"/>	<input type="text" value="0"/>	<input type="text" value="0"/>	<input type="text" value="0"/>	0
More than One Race	<input type="text" value="0"/>	<input type="text" value="0"/>	<input type="text" value="0"/>	<input type="text" value="0"/>	0
Total	0	0	0	0	0

Cumulative (Actual)

Racial Categories	Ethnic Categories									Total
	Not Hispanic or Latino			Hispanic or Latino			Unknown/Not Reported Ethnicity			
	Female	Male	Unknown/Not Reported	Female	Male	Unknown/Not Reported	Female	Male	Unknown/Not Reported	
American Indian/Alaska Native	<input type="text" value="0"/>	0								
Asian	<input type="text" value="0"/>	0								
Native Hawaiian or Other Pacific Islander	<input type="text" value="0"/>	0								
Black or African American	<input type="text" value="0"/>	0								
White	<input type="text" value="0"/>	0								
More than One Race	<input type="text" value="0"/>	0								
Unknown or Not Reported	<input type="text" value="0"/>	0								
Total	0	0	0	0	0	0	0	0	0	0

Instructions for Participant Level Data Upload

Participant level data file (CSV):

Download Participant Level Data Template

Upload Participant Level Data Attachment

Save and Keep Lock Save and Release Lock Save and Add Cancel and Release Lock Remove Report

Section 3 - Protection and Monitoring Plans.

3.1. Protection of Human Subjects

Add Attachment

Delete Attachment

View Attachment

If Claiming Exemptions: justify why the research meets the criteria for the exemption(s) claimed. If non-exempt, response must be commensurate with the study's risk level, size, and complexity. Must have 4 sections: Risks to Human Subjects, Adequacy of Protection Against Risks, Potential Benefits of the Proposed Research to Research Participants and Others, and Importance of the Knowledge to be Gained. Be sure that informed assent is included if applicable and appropriate protections for vulnerable populations is addressed, as applicable.

3.2. Is this a multi-site study that will use the same protocol to conduct non-exempt human subjects research at more than one domestic site?

Answer only if this is non-exempt human subjects research; Note that only the sIRB letter is needed and NIGMS does not request or review reliance agreements.

Yes No N/A

Single IRB plan attachment

Add Attachment

Delete Attachment

View Attachment

3.3. Data and Safety Monitoring Plan

Add Attachment

Delete Attachment

View Attachment

3.4. Will a Data and Safety Monitoring Board be appointed for this study?

Yes No

3.3 and 3.4 Required for CTs, otherwise optional but if the research is more than minimal risk or a vulnerable population is involved, then NIGMS wants a DSMP, which should include oversight by either an IMM (Independent Medical Monitor) or a Data Safety and Monitoring Board (DSMB). A DSMB is required if the risk is substantial even if not a CT. NIGMS requires notification of serious adverse effects within 24 hours.

3.5. Overall Structure of the Study Team

Only required for CTs

Add Attachment

Delete Attachment

View Attachment

Section 4 - Protocol Synopsis

Entire Section 4 is only required for CTs. Refer to instructions for required content.

4.1. Study Design

4.1.a. Detailed Description

4.1.b. Primary Purpose

4.1.c. Interventions

<input type="checkbox"/>	Intervention Type	
	Name	
	Description	

Add New Intervention

4.1.d. Study Phase

Is this an NIH-defined Phase III clinical trial? Yes No

4.1.e. Intervention Model

4.1.f. Masking

Yes No
 Participant Care Provider Investigator Outcomes Assessor

4.1.g. Allocation

4.2. Outcome Measures

X	Name	
	Type	
	Time Frame	
	Brief Description	

Add New Outcome

4.3. Statistical Design and Power

consult a statistician! Add Attachment Delete Attachment View Attachment

4.4. Subject Participation Duration

4.5. Will the study use an FDA-regulated intervention? Yes No

4.5.a. If yes, describe the availability of Investigational Product (IP) and Investigational New Drug (IND)/Investigational Device Exemption (IDE) status

Add Attachment Delete Attachment View Attachment

4.6. Is this an applicable clinical trial under FDAAA? Yes No

4.7. Dissemination Plan

Add Attachment Delete Attachment View Attachment

Requirements: Agree to register trial in ClinicalTrials.gov no later than 21 days after enrolling the 1st participant, include statement in consent forms that clinical trial information will be posted at ClinicalTrials.gov, agree to report results no later than one year after primary completion date in ClinicalTrials.gov. Note that PI must ensure this gets done if Project Lead does not.

NOTES for CT: All clinical trials must post a copy of a consent form used during the study on a Federal website, English language consent forms can be posted at ClinicalTrials.gov or Regulations.gov. Non-English consent forms can only be posted to Regulations.gov. Must be posted AFTER enrollment closes and no later than 60 days after the last study visit of any participant. NOT BEFORE enrollment closes.

Section 5 - Other Clinical Trial-related Attachments

Only required for CTs AND only if required by the FOA.

5.1. Other Clinical Trial-related Attachments

Add Attachments Delete Attachments View Attachments

In HSS, you will need to add Section 6. Milestones pre-award or at the next RPPR. If it's a CT, the milestones must match what's in CT.gov.